REVELATION BIOSCIENCES INC
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
REVB$4.11+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $717,582 | $525,273 |
| General and administrative | 1,184,556 | 1,094,574 |
| Total operating expenses | 1,902,138 | 1,619,847 |
| Loss from operations | (1,902,138) | (1,619,847) |
| Other (expense) income: | ||
| Change in fair value of warrant liability | 68,427 | 7,744,935 |
| Other (expense) income, net | (847,722) | 34,107 |
| Total other (expense) income, net | (779,295) | 7,779,042 |
| Net (loss) earnings | $(2,681,433) | $6,159,195 |
| Net (loss) earnings per share, basic | $(2.46) | $45.52 |
| Weighted-average shares used to compute net (loss) earnings per share, basic | 1,089,833 | 135,305 |
| Net (loss) earnings per share, diluted | $(2.46) | $37.07 |
| Weighted-average shares used to compute net (loss) earnings per share, diluted | 1,089,833 | 166,144 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.